China biotech InnoCare signs $3.35B Lilly deal, signaling shift to innovation leadership

InnoCare Pharma's strategic collaboration with Eli Lilly, potentially worth $3.35B, marks a shift in Chinese biotech deal-making from licensing individual drug candidates to broader research partnerships. This reflects China's transition from a follower to an innovation leader in the global biotech sector. The deal's structure and value suggest growing confidence in Chinese R&D capabilities, though the full financial impact depends on milestones.